Product Images Bortezomib

This appears to be a table or graph showing the percentage of patients remaining after a certain amount of time for two different types of treatments. There is also a p-value provided from a log-rank test. It is not clear what the treatments are or what condition they are being used to treat.*

This appears to be a survival analysis plot comparing R-CHOP therapy versus BRCAP therapy for certain patients in a study. The plot shows time (in months) on the x-axis and the number of subjects still alive on the y-axis. The survival curves for the two therapies appear to be significantly different based on the log-rank test with a p-value of less than 0.001. There were more patients receiving the R-CHOP therapy and the subjects at risk decreased with time.*

This appears to be a graph showing the proportion of patients over time who were taking either Bortezomib or Dexamethasone, with the number of patients remaining after each timepoint shown. The graph also includes percentages on the y-axis and time (in days) on the x-axis. The data shows a statistically significant difference between the two groups, as indicated by a p-value from a log-rank test.*

This appears to be a label for Bortezomib, a cytotoxic agent used for intravenous or subcutaneous use. The vial comes in a strength of 3.5mg, and should be protected from light and stored at a temperature between 15-30°C. The label contains information on reconstitution, dosage, and storage.*

This is a description of a drug named "Injection For BluePoint Laboratories". It should be stored at a temperature of 26°C with a limited excursion of 15°C to 30°C. The drug is manufactured by VSN Laboratories Private Limited located in Telangana, INDIA. It contains 3.5 mg boriezomid and 35 mg manniol. It is recommended for intravenous or subcutaneous use but caution must be taken as it is a cytotoxic agent. The package insert should be referred to for more information.*

Bortezomib for Injection is a medication that is administered through intravenous injection only. The solution needs to be mixed with sodium chloride to achieve a final concentration of 1 mg/mL. There are stickers that need to be placed on the vial and syringe indicating that it is for intravenous use with Bortezomib. Full instructions can be found in Section 2 of the package insert.*

Bortezomib for Injection in 0.9% Sodium Chloride to make a final concentration of 2-5 mg/mL subcutaneously. Place sticker on the vial or syringe. Please see the package insert for full instructions.*